<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Susceptibility to cytotoxic drugs was studied using an Epstein-Barr virus (EBV) genome-negative Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell line (Ramos) originating from the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and an in vitro EBV-converted Ramos cell line (B7) </plain></SENT>
<SENT sid="1" pm="."><plain>Decreased doubling time (DT) with increased saturation density (SD) and elevated [3H]<z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation were shown in B7, indicating more rapid cell proliferation and growth </plain></SENT>
<SENT sid="2" pm="."><plain>However, B7 was highly susceptible to cytotoxic drugs when compared to Ramos </plain></SENT>
<SENT sid="3" pm="."><plain>These results indicated whether the presence or absence of EBV genome in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells may be beneficial for evaluation of susceptibility to cytotoxic chemotherapy in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>